PSORIASIS

REAL-WORLD EFFICACY OF APREMILAST IN PATIENTS WITH MODERATE PLAQUE PSORIASIS: RESULTS FROM THE CORRONA PSORIASIS REGISTRY

J Merola [1] - A Gottlieb [2] - R Mclean [3] - J Cirulli [4] - C Williams [5] - G Linowski [5] - H Litman [3] - N Guo [3] - K Emeanuru [3] - B Strober [6]

Brigham And Women's Hospital, Harvard Medical School, Department Of Dermatology, Boston, United States [1] - Icahn School Of Medicine At Mount Sinai, Beth Israel Campus, Department Of Dermatology, New York, United States [2] - Corrona, Llc, Epidemiology, Waltham, United States [3] - Celgene Corporation, Global Medical Affairs, Summit, United States [4] - Celgene Corporation, Immunology & Inflammation, Summit, United States [5] - University Of Connecticut, Dermatology, Farmington, United States [6]

Introduction: Apremilast (APR) demonstrated efficacy and favorable safety/tolerability in the ESTEEM phase 3 trials in patients with moderate/severe psoriasis and in UNVEIL, a phase 4 trial in patients with moderate psoriasis. Less is known about real-world efficacy of APR in moderate psoriasis.

Objective: To evaluate efficacy among patients with moderate psoriasis and all psoriasis patients who initiated APR in the US Corrona Psoriasis Registry.

Materials and Methods: Included adult patients with psoriasis in the Corrona Psoriasis Registry from April 2015 to January 2018 who initiated APR and had a follow-up visit ~12 months post-APR initiation. Moderate psoriasis at APR initiation was defined as psoriasis-affected BSA of 3%-10%. Outcomes at 12 months included proportions of patients who achieved Investigator's Global Assessment x BSA score (IGAxBSA) ≤3, BSA <3%, BSA <1%, IGA 0/1, and DLQI score 0/1.

Results: Eighty-six patients initiated APR and had a 12-month visit; 43 had moderate psoriasis at APR initiation. In the moderate subset, mean (SD) age was 51.2 (15.4) years and 37% were female. At 12 months, 44% (95% CI: 30%-60%) of those with moderate psoriasis achieved IGAxBSA ≤3; 47% (32%-62%) achieved IGA 0/1. Proportions who achieved BSA <3% and BSA <1% were 44% (30%-60%) and 19% (9%-34%), respectively. The proportion who achieved DLQI 0/1 was 42% (28%-58%). Twelve-month outcomes were similar to the overall cohort for achieving IGAxBSA ≤3 (38%), IGA 0/1 (40%), BSA <3% (44%), and BSA <1% (21%). The proportion of moderate psoriasis patients who achieved IGAxBSA ≤3 in Corrona (44%) is similar to the proportion who achieved

PGAxBSA-75 at 52 weeks in the UNVEIL trial of APR in patients with moderate plaque psoriasis(42%).

Conclusion: APR efficacy in patients with moderate plaque psoriasis was similar to that among all patients initiating APR and consistent with UNVEIL results in patients with moderate psoriasis.